Fresh analysis indicates that people who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who stop traditional lifestyle programs.
Research printed in a leading medical journal demonstrates that while obese individuals frequently drop substantial amounts of their total mass while on the medication, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"People buying these medications must be informed of the danger of quick weight regain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
This pace of regain implies a return to original weight within about a year and a half.
Comparing Approaches
The study, which reviewed dozens of trials involving thousands of participants, contrasted the outcomes of the injectable medications with other pills.
The team note that people who lose weight through dieting typically experience a more gradual weight regain—around 100 grams monthly—once they finish.
Understanding the Fast Regain
Nutrition scientists propose the mechanism of the injections explains the amplified rebound.
The injections copy a natural hormone called GLP-1, which moderates appetite.
"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the system to produce less of its endogenous GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication leads to hunger is uncontrolled, making excessive eating much more probable."
A Chronic Issue?
Health authorities advise the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts contend that, considering the likelihood of relapse, the treatment might need to be life-long.
This perspective is echoed by pharmaceutical companies, who note that the results "highlight the persistent nature of obesity," similar to managing diseases like hypertension.
User Accounts
Users who have discontinued the medication describe a intense return of appetite.
"It was like a trigger that goes on and you're instantly ravenous," recalled one woman.
This difficulty is compounded if patients have not adopted permanent lifestyle or habit changes during therapy.
Widespread Adoption
Figures suggest that a significant number of adults in the UK have tried these injections in the past year, with interest remaining high.
- Adoption is greater among women than males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, experts caution that while these medications are powerful tools for weight loss, they are not a standalone solution and lasting health benefits hinges on combined behavioural changes.
